A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Vertex and partner CRISPR Therapeutics’ CRSP ... to offer enhanced patient benefit than Trikafta and become a new standard-of-care treatment in CF. It can potentially treat CF patients who ...
As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 ...